click below
click below
Normal Size Small Size show me how
Mental Health MOA
Mechanism of action of mental health medications
Question | Answer | Topic |
---|---|---|
Ethosuximide | Blocks T-Type Calcium channels, abundant on dendrites of neurones. Prevents excessive activity. | Epilepsy |
Gabapentin | Blocks glutamate stimulated Ca channels. Inhibits depolarisation-induced Ca influx at nerve terminals (decreased glutamate release) | Epilepsy |
Lamotrigine | Inhibits glutamate release. Suppresses repetitive neuronal firing by inhibiting sodium channels | Epilepsy |
Levetiracetam | Binds to synaptic vesicular protein SV2A --> alters synaptic neurotransmitter release | Epilepsy |
Phenytoin | Blocks Na+ channels and prolongs inactive state. Reduces synaptic release of glutamate and enhances GABA release. | Epilepsy |
Sodium Valproate | Blocks sodium channels, enhances GABA (by inhibiting the enzyme GABA transaminase) | Epilepsy |
Tiagabine | Inhibits GABA transporter responsible for removing extracellular levels of GABA. --> increased GABA in synapse --> increased inhibitory transmission | Epilepsy |
Topiramate | Blocks sodium channels. Potentiates effects of GABA (distinct binding site on GABA-A receptors | Epilepsy |
Vigabatrin | Irreversible inhibitor of GABA aminotransferase --> Increased levels of GABA released --> enhanced neuronal inhibition | Epilepsy |
Amitriptyline | inhibitor of amine reuptake from the synaptic cleft | Mood disorders |
Bupropion | Noradrenaline/dopamine-reuptake inhibitor (NDRI) | Mood disorders |
Doxepin | Selective H1 receptor blocker | Mood disorders |
Escitalopram (Lexapro) | SSRI | Mood disorders |
Fluoxetine (Prozac) | SSRI | Mood disorders |
Mirtazipine | Exerts effects on alpha adrenergic receptors, along with 5HT receptors and H1 receptors | Mood disorders |
Paroxetine (Paxil) | SSRI | Mood disorders |
Phenelzine | MAOI | Mood disorders |
Sertraline (Zoloft) | SSRI | Mood disorders |
Tranlycypromine | MAOI | Mood disorders |
Trazodone | Similar effects to SSRIs with additional effects on H1 receptors and alpha drenergic receptors | Mood disorders |
Venlafaxine | SNRI | Mood disorders |
Amantadine | Antiviral, releasing dopamine from intact dopamine terminals in the striatum | Parkinson's |
Apomorphine | Potent DA receptor agonist | Parkinson's |
Benzerazide | Co-beneldopa: Ldopa with a peripheral dopa decarboxylase inhibitor | Parkinson's |
Benzotropine | Antimuscarinic, block muscarinic cholinergic receptors can be used to alleviate this imbalance of dopamine | Parkinson's |
Bromocriptine | Agonist at D2 receptors, also treats hyperprolactinaemia | Parkinson's |
Carbidopa | Co-careldopa: Ldopa with a peripheral dopa decarboxylase inhibitor | Parkinson's |
Entacapone | COMT inhibitor | Parkinson's |
L-Dopa | Dopamine precursor (pro drug of dopamine) | Parkinson's |
MPTP | Toxin that causes Parkinson's | Parkinson's |
Orphenadrine | Antimuscarinic, block muscarinic cholinergic receptors can be used to alleviate this imbalance | Parkinson's |
Pergolide | Agonist at D1 and D2 receptors | Parkinson's |
Pramipexole | Agonist at D3 receptors | Parkinson's |
Rasagiline | Irreversibel inhibitor of MAO-B , more potent that selegiline | Parkinson's |
Rivastigmine | Acetylcholinesterase Inhibitor | Parkinson's |
Ropinirole | Agonist at D2 receptors | Parkinson's |
Selegiline | Irreversible inhibitor of MOA-B | Parkinson's |
Tolcapone | COMT inhibitor | Parkinson's |
Flupenthixol | D1 and D2 receptor powerful antagonist | Psychoses |
Haloperidol | First generation Antipsychotic, High D2 receptor affinity | Psychoses |
Clozapine | Old second generation antipsychotic, with greater affinity for 5HT2 receptors than D2, potent antagonist at D4 | Psychoses |
Olanzapine | Second generation antipsychotic with greater affinity for 5HT2 recpertors than D2, potent antagonist at D5 less risk of agranulocytosis than clozapine | Psychoses |
Risperidone | Second generation Antipsychotic | Psychoses |
Aripiprazole | Second generation Antipsychotic | Psychoses |
Pericyazine | Phenothiazine (group 2) first generation AntiPsych, moderate sedative effects with severe antimuscarinic but fewer extra pyrimidial side effects | Psychoses |
Pipotiazine | Phenothiazine (group 2) first generation AntiPsych, moderate sedative effects with severe antimuscarinic but fewer extra pyrimidial side effects | Psychoses |
Fluphenazine | Phenothiazine (group 3) first generation AntiPsych, fewer sedative and antimuscarinic effects, high extrapyrimidial side effects | Psychoses |
Prochlorperazine | Phenothiazine (group 3) first generation AntiPsych, fewer sedative and antimuscarinic effects, high extrapyrimidial side effects | Psychoses |
Acamprosate | GABA-A agonist & NMDA antagonist | alcohol dependence |
Reboxitine | Selective Noradrenaline reuptake inhibitor | Mood disorders |
Carbamazepine | Blocks sodium channels, Decreases neurotransmitter release. | Epilepsy |